Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage (LAA) in Patients With Atrial Fibrillation

Inclusion Criteria: * Documented paroxysmal, persistent or chronic non-valvular AF * Calculated CHA2DS2 -VASC score equal or greater than 2 and/or HAS-BLED score equal or greater than 2 * Patients eligible or non-eligible for lifelong, oral anticoagulation therapy * Life expectancy of at least 1 year * Written, informed consent by the patient or her/his legally-authorized representative for participation in the study Exclusion Criteria: * Suspected or known intracardiac thrombus * NYHA Class IV CHF * Patients who has unstable and intractable angina pectoris * ASD and/or atrial septal repair or closure device * Recent myocardial infarction within 3 months * Severe valvular heart disease, or implanted mechanical valve prosthesis * Large PFO with significant atrial septal aneurysm * Planned ablation procedure within 30 days of Occlutech LAA occluder® implant * Resting heart rate \> 110 bpm * Allergy to Nitinol, which is a result of nickel and/or titanium allergies * Stroke/TIA within the last 30 days * Thrombocytopenia, thrombocytosis, leukopenia, or anemia * Symptomatic carotid artery disease * LVEF \< 30% * Mitral valve stenosis